BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » European Bank for iPS Cells Launches Cells for Disease Modelling and Preclinical Research
What Massive Collaboration Can Create - European Bank for Induced Pluripotent Stem Cells (EBiSC) - Depositphotos_102306674_m-2015

European Bank for iPS Cells Launches Cells for Disease Modelling and Preclinical Research

April 13, 2016 By Cade Hildreth (CEO) 1 Comment

Recently the European Bank for induced pluripotent Stem Cells (EBiSC) announced the launch of its on-line catalogue of iPSCs for use in disease modeling and pre-clinical research. The cell lines were created and deposited by EBiSC partner labs and a broad range of external organisations.

Discover class-defining bioproduction tools.

Upcoming efforts will introduce to the bank a large number of Parkinson’s and Alzheimer’s Disease lines, as well as lines for diabetes, cardiovascular research, muscular dystrophies, neuropathic pain, and more. These new lines will be produced through external collaborations, as well as cell line creation within the EBiSC.

Specifically, EBiSC announced: 

EBiSC, the European Bank for induced pluripotent Stem Cells announces the public launch of its on-line catalogue of induced Pluripotent Stem Cells (iPSCs) which are available to academic and commercial scientists for use in disease modeling and other forms of pre-clinical research. (https://cells.ebisc.org). The initial collection of iPSCs available from the catalogue have been generated from a wide range of donors representing either specific disease backgrounds or healthy control donors.  The catalogue has been created by the EBiSC consortium – a public-private partnership project supported by the Innovative Medicines Initiative (IMI), of 27 organisations, comprising pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), small & medium-sized enterprises (SMEs) and academic institutions (www.ebisc.eu).

For the EBiSC iPSC catalogue, see https://cells.ebisc.org

Rooster DevServices

For further information on EBiSC and the project partners see www.ebisc.eu.

For more information on the Innovative Medicines Initiative (IMI), visit www.imi.europa.eu

bitbio

 

Rate this post

Filed Under: iPS Cells, Stem Cells Tagged With: disease modeling, EBiSC, EFPIA, iPSC, Roslin Cell Sciences

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Comments

  1. Jerry Siegel says

    April 19, 2016 at 8:26 am

    So, just a question here – do the universities give up all of their rights to the cell lines they generate and provide or are they included in any downstream revenues that pharma derive from their lines, as would be normal for a university licensing deal?

    Reply

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.